<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692313</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00068487</org_study_id>
    <nct_id>NCT02692313</nct_id>
  </id_info>
  <brief_title>Dose Response of Epinephrine</brief_title>
  <acronym>Epineprhine</acronym>
  <official_title>Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer
      duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial
      function and atherothrombotic balance in humans. The specific aim of our study will be to
      determine the dose response effects of the key ANS counterregulatory hormone epinephrine on
      endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in
      healthy humans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilation (FMD) of the brachial artery</measure>
    <time_frame>From baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))</time_frame>
    <description>Measurements of FMD will be taken at baseline (pre intervention) and end of glucose clamp (post intervention) and the maximal % change determined</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Saline infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.015ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.03 ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinephrine infusion-0.06 ug/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Dose response of epinephrine infusion</description>
    <arm_group_label>Epinephrine infusion-0.015ug/kg/min</arm_group_label>
    <arm_group_label>Epinephrine infusion-0.03 ug/kg/min</arm_group_label>
    <arm_group_label>Epinephrine infusion-0.06 ug/kg/min</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline infusion</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy controls age 18-55 yr.

          -  Body mass index &gt;21 kg Â· m-2

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Subjects unwilling or unable to comply with approved contraception measures

          -  Subjects unable to give voluntary informed consent

          -  Subjects on anticoagulant drugs, anemic or with known bleeding diatheses

          -  Subjects with a history of severe, uncontrolled hypertension, heart disease,
             cerebrovascular incidents

          -  Current tobacco use

          -  Subjects with any known allergies to any of the study medications being used

        Physical Exam Exclusion Criteria

          -  Uncontrolled severe hypertension (i.e., blood pressure greater than 160/100)

          -  Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia)

          -  Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study
             visit)

          -  Hepatic failure / jaundice

          -  Renal failure

          -  Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to
             enrollment

          -  Fever greater than 38.0 degrees C

        Screening Laboratory Tests Exclusion Criteria

          -  Hematocrit lower than 32 %

          -  White blood cell (WBC) count lower than 3 thou/ul or greater than 14 thou/ul

          -  Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum
             glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range

          -  Alkaline phosphatase greater than 150U/L

          -  Total bilirubin (TBil) greater than 2 mg/dl

          -  Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2

          -  Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C

          -  Any abnormal cardiac response during multi-stage exercise test (if over 40 years of
             age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Davis, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Tate</last_name>
    <phone>410-706-5643</phone>
    <email>dtate@medicine.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maia Mikeladze, MD</last_name>
    <phone>410-706-5626</phone>
    <email>mmikeladze@medicine.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Tate</last_name>
      <phone>410-706-5643</phone>
    </contact>
    <contact_backup>
      <last_name>Maka Hedrington, MD</last_name>
      <phone>410-706-5636</phone>
    </contact_backup>
    <investigator>
      <last_name>Stephen N Davis, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis, MBBS</investigator_full_name>
    <investigator_title>Chairman of Medicine</investigator_title>
  </responsible_party>
  <keyword>epinephrine</keyword>
  <keyword>counterregulation</keyword>
  <keyword>dose responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

